Gaithersburg-based MedImmune is the global biologics arm of AstraZeneca PLC, with approximately 3,500 employees worldwide.
MedImmune’s Synagis® product is the first monoclonal antibody approved for the prevention of an infectious disease, as well as the first such drug to be safely used in children.
Synagis® prevents a serious lower respiratory tract disease caused by the respiratory synctial virus (RSV), prominent in the Northern Hemisphere during the winter months. RSV is the most common respiratory infection for infants and children. Approximately 50 percent of all infants are infected with RSV during their first year of life; nearly all children have been infected at least once by the time they reach their second birthday.